PMID- 27667027
OWN - NLM
STAT- Publisher
LR  - 20191120
IS  - 2045-2322 (Electronic)
IS  - 2045-2322 (Linking)
VI  - 6
DP  - 2016 Sep 26
TI  - Efficacy and safety of TNF-alpha inhibitors for active ankylosing spondylitis 
      patients: Multiple treatment comparisons in a network meta-analysis.
PG  - 32768
LID - 10.1038/srep32768 [doi]
LID - 32768
AB  - Ankylosing spondylitis (AS) is an inflammatory rheumatic disease with impact on 
      axial skeleton, peripheral joints and enthuses, and it may result in severe 
      disabilities of those parts. Tumor necrosis factor-alpha (TNF-alpha) inhibitors are 
      considered as an effective treatment for patients with active AS. In this study, 
      we conducted a network meta-analysis to compare the clinical outcomes of active 
      AS patients treated with TNF-alpha inhibitors. Randomized controlled trials (RCTs) 
      evaluating the efficacy and safety of TNF-alpha inhibitors were retrieved in 
      literature search and selected for meta-analysis. Changes in ASAS20 response, 
      ASAS40 response and BASDAI 50% response were regarded as efficacy outcomes; 
      serious adverse events (SAE) and all cause withdrawals were regarded as safety 
      outcomes. Both traditional pairwise meta-analysis and network meta-analysis were 
      performed. The results showed that adalimumab and infliximab had better clinical 
      outcomes. Infliximab consistently appeared to be the most effective TNF-alpha 
      inhibitors with a high risk of adverse events for patients with active AS; 
      meanwhile, adalimumab ranked highest with respect to adverse effects with 
      efficacy secondary to infliximab. As a result, we were unable to conclude the 
      optimal TNF-alpha inhibitor and this issue should be solved by future researchers.
FAU - Liu, Wei
AU  - Liu W
AD  - Department of Rheumatology and Immunology, First Teaching Hospital of Tianjin 
      University of Traditional Chinese Medicine, Tianjin, China.
FAU - Wu, Yuan-Hao
AU  - Wu YH
AD  - Department of Rheumatology and Immunology, First Teaching Hospital of Tianjin 
      University of Traditional Chinese Medicine, Tianjin, China.
AD  - Institute of Basic Research in Clinical Medicine, China Academy of Chinese 
      Medical Science, Beijing 100700, P. R. China.
FAU - Zhang, Lei
AU  - Zhang L
AD  - Department of Rheumatology and Immunology, First Teaching Hospital of Tianjin 
      University of Traditional Chinese Medicine, Tianjin, China.
FAU - Liu, Xiao-Ya
AU  - Liu XY
AD  - Department of Rheumatology and Immunology, First Teaching Hospital of Tianjin 
      University of Traditional Chinese Medicine, Tianjin, China.
FAU - Bin Xue
AU  - Bin Xue
AD  - Department of Rheumatology and Immunology, First Teaching Hospital of Tianjin 
      University of Traditional Chinese Medicine, Tianjin, China.
FAU - Bin Liu
AU  - Bin Liu
AD  - Department of Rheumatology and Immunology, First Teaching Hospital of Tianjin 
      University of Traditional Chinese Medicine, Tianjin, China.
FAU - Wang, Yi
AU  - Wang Y
AD  - Department of Rheumatology and Immunology, First Teaching Hospital of Tianjin 
      University of Traditional Chinese Medicine, Tianjin, China.
FAU - Ji, Yang
AU  - Ji Y
AD  - The 272nd Hospital of Chinese People's Liberation Army, Tianjin, China.
LA  - eng
PT  - Journal Article
DEP - 20160926
PL  - England
TA  - Sci Rep
JT  - Scientific reports
JID - 101563288
PMC - PMC5036083
EDAT- 2016/09/27 06:00
MHDA- 2016/09/27 06:00
PMCR- 2016/09/26
CRDT- 2016/09/27 06:00
PHST- 2016/01/07 00:00 [received]
PHST- 2016/08/02 00:00 [accepted]
PHST- 2016/09/27 06:00 [entrez]
PHST- 2016/09/27 06:00 [pubmed]
PHST- 2016/09/27 06:00 [medline]
PHST- 2016/09/26 00:00 [pmc-release]
AID - srep32768 [pii]
AID - 10.1038/srep32768 [doi]
PST - epublish
SO  - Sci Rep. 2016 Sep 26;6:32768. doi: 10.1038/srep32768.